Alpha Fetoprotein Testing Market: By Test Type (ELISA Assays, Chemiluminescent Immunoassays, Immunofluorescence Assays, Rapid Tests), By Indication (Pregnancy, Hepatocarcinoma, Testicular Cancer, Ovarian Cancer, and Others), By End User (Academic and Research Organizations, Contract research organizations (CROs), Hospitals and Clinics and Others) And By Geography (North America, Europe, Asia-Pacific, Middle East And Africa, and South America) and Forecast To 2030.

Alpha Fetoprotein Testing Market size was valued at USD 668.3 million in 2023 and is poised to grow at a CAGR of 7.1% from 2024-2030. Alpha-fetoprotein (AFP) is a protein that is typically produced by the fetal liver, yolk sac, and gastrointestinal tract during pregnancy. It is the fetal form of serum albumin, which is the main protein in adult blood. AFP levels are usually high in the fetus but decrease significantly after birth and are typically very low in healthy adults. The alpha-fetoprotein (AFP) test is a blood test for pregnant people and is prescribed to people with liver diseases, and germline diseases such as hepatocarcinoma, testicular cancer, ovarian cancer, and so on. The Alpha-Fetoprotein (AFP) testing market encompasses the commercial landscape for products and services related to AFP testing. The presence of AFP is usually low in healthy individuals under 20 ng/ml, whereas pregnant women and diseased individuals have a range of 500-1000 ng/ml. If the individual has around 200ng/ml of AFP, then an AFP-L3 test is prescribed, so that diagnosis can be more accurate.

The increasing prevalence of chronic liver conditions, rise in the occurrence of hepatitis, and adoption of prenatal care and screening of abnormalities, accuracy and efficiency of AFP tests, and higher spending on healthcare are the main drivers of this market. Even though the accuracy is high comparing other tests occurrence of false positives and false negatives is still a major restraint. The high expense of cutting-edge diagnostic equipment and the need for skilled personnel are also acting as restraints. Automation of testing systems and the development of POCT of AFP tests both allow for quicker results and improved patient management. Expanding healthcare infrastructure in developing countries and increasing awareness among people for early diagnosis of diseases serve as the main opportunities for companies in this market.

Recent Development In Alpha-fetoprotein Testing Market:

• In December 2021, Roche declared the introduction of NAVIFY® Oncology Hub, its most recent digital solution to further improve clinical decision backing and workflow optimization for oncologists and oncology care teams.
• In November 2021, Roche declared the introduction of the cobas® 5800 System, a novel molecular laboratory tool, in countries receiving the CE mark. The Cobas 5800 System assists in attending to challenges that the laboratories are encountering from a boost in patient testing, and the requirement for a more diverse testing menu including AFP tests while offering significant and timely outcomes.